Stock Analysis
- Israel
- /
- Real Estate
- /
- TASE:MDPR
Medipower (Overseas) Full Year 2023 Earnings: EPS: US$0.16 (vs US$0.026 in FY 2022)
Medipower (Overseas) (TLV:MDPR) Full Year 2023 Results
Key Financial Results
- Revenue: US$38.6m (up 2.9% from FY 2022).
- Net income: US$8.00m (up 495% from FY 2022).
- Profit margin: 21% (up from 3.6% in FY 2022).
- EPS: US$0.16 (up from US$0.026 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medipower (Overseas)'s share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that Medipower (Overseas) is showing 3 warning signs in our investment analysis and 1 of those shouldn't be ignored...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TASE:MDPR
Medipower (Overseas)
Operates as a commercial real estate company in the United States, Canada, and Bulgaria.
Good value with proven track record.
